Skip to content

Evolus EOLS Price / sales

Price / sales at other companies

AbbVie logo
AbbVieABBV
6.1×-0.3×

Other financials

Income statement

See full
Revenue$73.1M+6.7%
Gross profit$48.9M+4.8%
Operating income-$6.8M+54.9%
Net income-$10.7M+43.5%
EPS (diluted)-$0.16+46.7%

Balance sheet

See full
Cash & equivalents$49.8M-26.7%
Total debt$164.9M-4.1%
Total equity-$28.8M-336%
Total assets$220.6M+3.4%

Cash flow

See full
Operating cash flow-$10.0M+36.3%
CapEx$415.0K+30.1%
Free cash flow-$10.4M+35.0%

Valuation

See full
Market cap$470.86M-21.3%
Enterprise value$585.97M-16.6%

Profitability

See full
Gross margin66.1%-2.4pp
Operating margin-13.7%-1.9pp
Net margin-14.4%-3.3pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio-0.3×

Where this comes from

Calculated from Evolus’s reported figures.

Based on the most recent quarter.

The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evolus's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolus's price / sales?
Evolus (EOLS) reported price / sales of 0.9× in Q1 2026.
How has Evolus's price / sales changed year-over-year?
Evolus's price / sales decreased by 68.1% year-over-year, from 2.8× to 0.9×.
What is the long-term trend for Evolus's price / sales?
Over 5 years (2020 to 2025), Evolus's price / sales has grown at a -15.2% compound annual growth rate (CAGR), from 3.3× to 1.5×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.